• Tunable Human Intestinal Organoids: Balancing Renewal and Di

  2026-04-25

  This study pioneers a human intestinal organoid culture system that enables precise, reversible control over stem cell self-renewal and differentiation using small molecule modulators. The findings provide a scalable platform with enhanced cellular diversity, addressing limitations of traditional organoid methods and facilitating high-throughput biomedical research.

• GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Modula

  2026-04-24

  The referenced study elucidates how upregulation of glutamate transporter 1 (GLT-1) in astrocytes attenuates neuronal apoptosis and cognitive dysfunction after traumatic brain injury (TBI), primarily through inhibition of the CB1-CREB signaling pathway. The findings highlight a mechanistic link between endocannabinoid signaling, astrocytic glutamate clearance, and neuroprotection, offering new experimental strategies for memory impairment research.

• Benzyl Quinolone Carboxylic Acid (BQCA): Reliable M1 Modulat

  2026-04-24

  This in-depth article addresses real laboratory challenges in cell-based and neuronal assays, demonstrating how Benzyl Quinolone Carboxylic Acid (BQCA, SKU C3869) enables precise, reproducible modulation of M1 muscarinic acetylcholine receptor signaling. Integrating evidence from recent mechanistic studies, we outline protocol benchmarks, interpretability, and vendor reliability to optimize experimental outcomes for Alzheimer's disease research and cognitive function modulation.

• Amikacin (BAY416651): Applied Workflows for Antibiotic Resis

  2026-04-23

  Amikacin (BAY416651) stands apart in antibiotic resistance research due to its stability against most aminoglycoside-modifying enzymes and robust bactericidal activity. This guide delivers advanced protocols, troubleshooting insights, and novel delivery strategies, including dendritic cell-mediated targeting of mycobacterial granulomas, to maximize research impact.

• Thiamet G and O-GlcNAcase Inhibition: Beyond Neurodegenerati

  2026-04-23

  Explore how Thiamet G, a potent O-GlcNAcase inhibitor, unlocks new insights into O-GlcNAcylation, cellular iron homeostasis, and disease modeling. This article uniquely connects molecular mechanism to translational assay design, offering actionable guidance for advanced researchers.

• Applied Insights with EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Dual

  2026-04-22

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) from APExBIO empowers researchers to simultaneously track mRNA delivery and translation in live cells, thanks to its dual Cy5 and EGFP fluorescence. This advanced tool streamlines mRNA delivery assays, immune evasion studies, and nanoparticle optimization with unmatched protocol flexibility and real-time quantification.

• Nanoparticle Delivery of PTEN mRNA Reverses Trastuzumab Resi

  2026-04-22

  This article reviews recent research demonstrating that nanoparticle-mediated systemic delivery of PTEN mRNA can restore trastuzumab sensitivity in HER2-positive breast cancer. The study highlights mechanistically targeted mRNA therapy as a promising approach to overcoming drug resistance in oncology.

• Palomid 529: Targeting PI3K/Akt/mTOR to Overcome ESCC Resist

  2026-04-21

  This thought-leadership article explores how Palomid 529 (P529), a dual mTORC1/mTORC2 inhibitor from APExBIO, enables translational researchers to address metastasis and chemoresistance in esophageal squamous cell carcinoma (ESCC). Synthesizing mechanistic insights from recent RCN2 research, it provides actionable guidance on deploying P529 in advanced cancer models, benchmarks experimental parameters, and clarifies the translational potential of PI3K/Akt/mTOR pathway inhibition.

• Aztreonam: Applied Workflows for Gram-Negative Resistance Re

  2026-04-21

  Aztreonam’s unique profile as a synthetic monocyclic β-lactam antibiotic enables precision targeting of Gram-negative aerobic bacteria in experimental workflows. This article details advanced use-cases, stepwise protocols, and troubleshooting strategies, leveraging recent data and APExBIO’s trusted sourcing for reproducible, high-impact research.

• Ruxolitinib Phosphate: Advanced JAK/STAT Pathway Modulation

  2026-04-20

  Ruxolitinib phosphate (INCB018424) empowers researchers to dissect JAK/STAT signaling with precision, offering robust selectivity for JAK1/JAK2 and proven efficacy in both autoimmune and oncology models. This guide details practical protocols, troubleshooting tips, and translational insights, leveraging new mechanistic evidence for assay optimization.

• Cyclophilin A Is Essential for Cyclosporine Immunosuppressio

  2026-04-20

  This study demonstrates that cyclophilin A is the primary intracellular mediator for the immunosuppressive action of cyclosporine. By using cyclophilin A-deficient mice, the authors reveal that loss of this protein confers resistance to cyclosporine-mediated immune response suppression, providing direct evidence for its central mechanistic role in transplantation immunology research.

• E-64d: Precision Cysteine Protease Inhibition for Cell Death

  2026-04-19

  E-64d is a membrane-permeable, irreversible cysteine protease inhibitor that enables precise dissection of complex cell death pathways in both in vitro and in vivo models. Its robust inhibition of calpain and cathepsins unlocks reproducible, data-rich workflows for apoptosis, neuroprotection, and lysoptosis research—backed by cutting-edge experimental evidence and optimized protocols.

• Angiotensin (1-7): Applied Workflows & Experimental Optimiza

  2026-04-18

  Angiotensin (1-7), an endogenous heptapeptide hormone, is redefining experimental design in anti-fibrotic, anti-inflammatory, and translational research. This article delivers stepwise protocol optimizations, workflow integration strategies, and troubleshooting guidance—empowering bench scientists to unlock the full potential of APExBIO’s ultrapure Angiotensin (1-7) for advanced disease modeling.

• Olaparib (AZD2281): Advanced Workflows for DNA Damage Respon

  2026-04-17

  Optimized for precision, Olaparib (AZD2281) enables robust DNA damage response assays and innovative tumor radiosensitization studies—especially for BRCA-deficient models. This article distills the latest experimental advances and troubleshooting strategies, guided by peer-reviewed evidence and real-world protocol tips.

• BI 2536 as a Quantitative Tool for Dissecting Cancer Cell Fa

  2026-04-16

  Discover how BI 2536, a potent PLK1 inhibitor, enables precise measurement of proliferation versus cell death in cancer research. This article uniquely bridges mechanistic detail with advanced assay interpretation using recent systems biology insights.

11316 records 1/755 page Next 12345 下5页 Last page